Effectiveness and tolerability of rimegepant in the acute treatment of migraine: a real-world, prospective, multicentric study (GAINER study)

Abstract Background Rimegepant, a novel oral calcitonin gene-related peptide receptor antagonist, has been recently approved for the acute migraine treatment. While its efficacy was confirmed in randomized clinical trials, no data is available regarding real-life effectiveness and tolerability. GAIN...

Full description

Saved in:
Bibliographic Details
Main Authors: Luigi Francesco Iannone, Gloria Vaghi, Gabriele Sebastianelli, Francesco Casillo, Antonio Russo, Marcello Silvestro, Francesca Pistoia, Giorgio Dalla Volta, Matteo Cortinovis, Alberto Chiarugi, Danilo Antonio Montisano, Maria Pia Prudenzano, Sabina Cevoli, Edoardo Mampreso, Gianluca Avino, Marina Romozzi, Mariarosaria Valente, Carla Fasano, Stefania Battistini, Antonio Granato, Elisa Maria Piella, Innocenzo Rainero, Raffaele Ornello, Roberto De Icco, On behalf of the Italian Headache Registry (RICe) Study Group
Format: Article
Language:English
Published: BMC 2025-01-01
Series:The Journal of Headache and Pain
Subjects:
Online Access:https://doi.org/10.1186/s10194-024-01935-8
Tags: Add Tag
No Tags, Be the first to tag this record!